Novartis today announced the results of an updated analysis of a Phase III trial evaluating invasive disease-free survival in patients with HR+/HER2- early breast cancer treated with Kisqali (ribociclib), after a median follow-up of 33.3 months.

The results reinforce the benefit observed in the previous interim analysis, with a 25.1% reduction in the risk of disease recurrence in these patients treated with Kisqali + standard endocrine therapy, compared with standard endocrine therapy alone.

"As clinicians, we know that patients diagnosed with HR+/HER2- early breast cancer remain at risk of recurrence for decades, despite adjuvant endocrine therapy," says Gabriel N. Hortobagyi, Professor of Breast Medical Oncology, University of Texas MD Anderson Cancer Center.

"The updated results reinforce ribociclib's potential to help address these needs for the broader at-risk population without additional disruptions to patients' quality of life compared to endocrine therapy alone.

These late-breaking data will be presented at the 2023 annual meeting of the San Antonio Breast Cancer Symposium (SABCS).

Copyright (c) 2023 All rights reserved.